RedHill Biopharma (NASDAQ: RDHL) CFO details ADS, RSU and option holdings
Rhea-AI Filing Summary
RedHill Biopharma Ltd. Chief Financial Officer Ingber Razi filed a Form 3 reporting existing equity interests in the company, rather than new open‑market trades. The filing lists American Depositary Shares (ADSs), restricted share units (RSUs) and stock options tied to Ordinary Shares.
The holdings include 27,756 unvested RSUs, each for one ADS, with each ADS representing 10,000 Ordinary Shares of par value NIS 0.01. The filing also notes 6,691 ADSs that are convertible at any time with no expiration date, plus fully vested stock options to purchase 20,000, 30,000, 170,000 and 230,000 Ordinary Shares at fixed exercise prices per ADS, expiring between August 29, 2028 and April 28, 2031.
Positive
- None.
Negative
- None.
Insider Trade Summary
6 transactions reported
Mixed
6 txns
Insider
Ingber Razi
Role
Chief Financial Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | American Depositary Shares | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Stock Option (Right to Buy) | -- | -- | -- |
| holding | Ordinary Shares | -- | -- | -- |
Holdings After Transaction:
American Depositary Shares — 66,910,000 shares (Direct);
Stock Option (Right to Buy) — 450,000 shares (Direct);
Ordinary Shares — 277,560,000 shares (Direct)
Footnotes (6)
- F1. Represents 27,756 unvested restricted share units ("RSUs"), each with respect to one American Depositary Share ("ADS"), which represents 10,000 ordinary shares, par value NIS 0.01 per share ("Ordinary Shares"), of RedHill Biopharma Inc. (the "Issuer"). The RSUs are subject to time-based vesting conditions and are settled in Ordinary Shares.
- F2. Represents 6,691 ADSs, which are convertible at any time, at the holder's election and have no expiration date.
- F3. Represents stock option to purchase 20,000 Ordinary Shares (equivalent to 2 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on August 29, 2028.
- F4. Represents stock option to purchase 30,000 Ordinary Shares (equivalent to 3 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $5,000 per ADS and the option expires on May 6, 2029.
- F5. Represents stock option to purchase 170,000 Ordinary Shares (equivalent to 17 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,720 per ADS and the option expires on June 30, 2030.
- F6. Represents stock option to purchase 230,000 Ordinary Shares (equivalent to 23 ADSs), issued to the reporting person pursuant to the RedHill 2010 Option Plan. The shares underlying this stock option are fully vested and exercisable. The exercise price of this stock option is $7,080 per ADS and the option expires on April 28, 2031.
AI-generated analysis. How Rhea-AI works. Not financial advice.
FAQ
What does RedHill Biopharma (RDHL) CFO Ingber Razi report owning on this Form 3?
The CFO reports existing holdings of ADSs, unvested RSUs and stock options. These positions relate to Ordinary Shares of RedHill Biopharma Ltd. and reflect equity-based compensation and ownership, not new open-market purchases or sales.
What stock options are reported by RedHill Biopharma (RDHL) CFO on Form 3?
The CFO reports fully vested stock options to purchase 20,000, 30,000, 170,000 and 230,000 Ordinary Shares under the RedHill 2010 Option Plan. Each grant has a stated exercise price per ADS and specific expiration dates between 2028 and 2031.
When do the RDHL CFO’s reported stock options expire?
The stock options described in the filing expire on August 29, 2028, May 6, 2029, June 30, 2030 and April 28, 2031. Each option grant is fully vested and exercisable, with an exercise price specified per American Depositary Share.
Are the equity awards reported by the RDHL CFO already vested?
The filing explains that all listed stock options are fully vested and exercisable, but the 27,756 RSUs are unvested and subject to time-based vesting. Once vested, these RSUs are settled in Ordinary Shares corresponding to the linked American Depositary Shares.